Dermatology
Sanoderm are committed to the development of innovative new therapies for the treatment of common dermatological disorders.
Onychomycosis
(Fungal Nail)
Tinea Pedis
(Athlete's Foot)
Atopic Dermatitis
(Eczema)
Other Conditions
Nanomedicine
Sanoderm applies the latest developments in complex nanotechnology to create more effective, safer, and easier to use topical treatments.
Nanopolymer Drug Delivery Systems
5
Drugs in our pipeline
13
Patents and exclusive licenses
15
Innovation in markets valued at >$15m
News
November 13th, 2023
Sanoderm Meets Primary and Secondary Endpoints in Phase 2b Trial in Onychomycosis
Primary endpoint (negative culture and/or clear nail growth) met with 83.3% response rate Secondary endpoints met at Week 52 after 9-months off treatment Limited Sanoderm, a pharmaceutical company focused on developing innovative, topical nanomedicines ...Continued
October 17th, 2023
A warm welcome to Megan!
We'd like to extend a warm welcome to our new Laboratory Technician, Megan Dawson. Megan joins us with a Masters in Medical Microbiology from the University of Manchester, and after gaining lots of relevant skills in an associate practitioner ...Continued
July 4th, 2023
Phase 2b Trial in Fungal Nail Infection Completed
Sanoderm is pleased to announce the completion of our European Phase 2b trial of BB2603 (BBTAF202). This trial is assessing the efficacy and safety of different doses of BB2603, a new topical anti-fungal ...Continued
